Physician profile
Jing Jiang
NPI 1043263395
$1,840.28
in general payments reported to CMS, 2019-2025
11 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $63.33 · 2021: $386 · 2022: $542 · 2023: $252 · 2024: $227 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $819.55 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $350.52 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $153.68 | 2024-2025 | Voquezna |
| Shionogi INC | $125.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $125.00 | 2022 | |
| Ardelyx, INC. | $88.22 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $53.44 | 2020-2021 | |
| Madrigal Pharmaceuticals | $53.21 | 2024-2025 | Resmetirom, Rezdiffra |
| Aimmune Therapeutics, INC. | $26.80 | 2025 | Vowst |
| Gilead Sciences, INC. | $25.11 | 2020 | |
| Nestle Healthcare Nutrition INC. | $19.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jing Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.